View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

C-Rad AB: 1 director

A director at C-Rad AB bought 8,000 shares at 32.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

Erik Cassel
  • Erik Cassel

C-RAD AB - Resilient despite weaker end markets

Exceptional Q3 sales and EBIT, but orders came in weak We cut ’24e EBIT by 3% on end-market weakness Fair value range of SEK 45-95/share

Erik Cassel
  • Erik Cassel

Sector Fast Comment - Hospital data update

Better hospital margins in August Congress passed supportive spending bill Small positive for companies with capex exposure

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Record heat on orders beat

Remarkable order intake 35% better than ABGSCe ‘23e EBIT up 8% and ‘24e up 4% Fair value range of SEK 45-95/share

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Exceptional order intake

Order intake 35% better than ABGSCe Strength in APAC drove 9% sales beat Cons EBIT estimates likely to come up 5%

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Held back as APAC slows

Opex higher than expected and eradicated earnings ‘22e EBIT down 38%, ‘24e relatively unchanged Share -34% YTD and mid-term prospects unchanged

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Softer as APAC comes to a halt

Orders 2% better, sales 3% below, EBIT 94% below Lost installations should come back in H2 High growth, attractive position, at large discount to peers

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Rolling with the Omicron punches

Omicron softens installations and orders in Q1’22e Sales down 3-2% ’22-24e on FX and supply chain High non-cyclical growth at 54% discount to peers

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - New guidelines should accelerate growth

We expect higher growth on the back of new guidelines EBIT estimates up 12-16% for ’22e-’24e Defensive, high growth and valued 58% below peers

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Setting new record highs

Second gross margin record in a row at 66% Order intake 15% better than we expected Strong setup for ‘22e recovery at 50% discount to peers

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Solid Q3 and on track for a great 2022

Strong margins behind 18% earnings beat Expect accelerating order intake in ‘22e 45% EBIT CAGR ’20-‘25e, valued 56% lower than peers

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Even closer to becoming standard of care

New partnership with Accuray Now working with all the major radiotherapy players Strong signal value of becoming standard of care

Jakob Lembke ... (+2)
  • Jakob Lembke
  • Rickard Anderkrans

C-RAD AB - Yet another strong quarter in the books

51% organic growth and 12% EBIT beat Strong performance indicating market share gains Currently trading at ’21-23e EV/sales of 7-5x

Jakob Lembke ... (+2)
  • Jakob Lembke
  • Rickard Anderkrans

C-RAD AB - Q2 EBIT above expectations

41% organic growth and 12% better EBIT Life cycle business up 52% y-o-y Webcast at 11.00 CET

Jakob Lembke ... (+2)
  • Jakob Lembke
  • Rickard Anderkrans

C-RAD AB - Another court win versus former employee

Court rules in favor of C-RAD versus former employee… … for the fourth consecutive time Recent order momentum has been strong

Jakob Lembke ... (+2)
  • Jakob Lembke
  • Victor Forssell

C-RAD AB - Accurately positioned for growth

Taking leadership in Surface Guided Radiation Therapy C-RAD’s technology becoming a standard-of-care tool Solid growth path with SEK 1.4bn annual market potential

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch